Dr Sheel Mehta
/content/dam/genesiscare/headshots/uk-doctor-headshots/Sheel Mehta.jpg

Dr Sheel Mehta

Dr Sheel Mehta
Sheel
Mehta
MBBS iBSc MRCP FRCR, Consultant Clinical Oncologist

Languages spoken

English

Expert in

Systemic therapy, image-guided radiotherapy, and prostate brachytherapy.

Overview

Special clinical interest in urological and cancers

Dr Sheel Mehta is a Consultant Clinical Oncologist specialising in the treatment of prostate and bladder cancer. She provides treatment with systemic therapy (chemotherapy, immunotherapy and hormone therapy), image guided radiotherapy and prostate brachytherapy.

She qualified from medical school at University College London in 2010 with distinctions in Medicine and Surgery. Her medical and oncological training was at the Royal Marsden Hospital, Guy’s and St Thomas’ Hospitals and the Royal Surrey County Hospital.

She has completed a Diploma in Oncology, and a fellowship in Brachytherapy at the Royal Surrey County Hospital. She currently works at the Royal Surrey County Hospital and continues to have a keen research interest particularly in radiotherapy and brachytherapy.

Career position

NHS Hospital

  • Royal Surrey County Hospital NHS Trust, East Surrey Hospital

Professoinal memberships

  • Fellow of the Royal College of Radiologists (RCR)
  • Member of the Royal College of Physicians (MRCP)
  • Member of the European Society of Therapeutic Radiation Oncology (ESTRO)

Expertise and interests

Dr Mehta has clinical interests in urological cancers.

Publications

  • Lewis S, Uribe J, Bourke V, Deering C, Higgins D, Mehta S, Mikropoulos C, Otter S, Perna C, Khaksar S, Laing R, Langley S. Long-term survival after low-dose-rate brachytherapy for prostate cancer: the Royal Surrey experience. BJU International. 2022;129(6):723-730. Available here.
  • Langley S, Laing R, Khaksar S, Perna C, Otter S, Mehta S, Uribe-Lewis S, Uribe J. In regard to Parry et al. International Journal of Radiation Oncology Biology Physics. 2021;110(3):912-913. Available here.
  • Langley S, Uribe J, Uribe-Lewis S, Mehta S, Mikropoulos C, Perna C, Otter S, Horton A, Cunningham M, Higgins D, Langley S, Deering C, Khaksar S. Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer? Brachytherapy. 2022;21(6):870-876. Available here.
  • Uribe-Lewis S, Uribe J, Deering C, Langley S, Higgins D, Whiting D, Metawe M, Khaksar S, Mehta S, Mikropoulos C, Otter S, Perna C, Langley S. Net survival of men with localized prostate cancer after LDR brachytherapy. Brachytherapy. 2024;23(3):329-334. Available here.